Matthew K. Fust - 17 Oct 2024 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Reporting relationship: Director
Issuer ticker: NMRA
Reported as of: 17 Oct 2024
Net transaction value: -$243,923
SEC form: 4
Accepted by SEC: 18 Oct 2024, 18:25:19 UTC
Prior SEC filing: 20 Jun 2024
Next SEC filing: 18 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Joshua Pinto, as Attorney-in-Fact for Matthew K. Fust

Key filing fact

Matthew K. Fust filed Form 4 for Neumora Therapeutics, Inc. (NMRA) on 18 Oct 2024.

Key facts

This page summarizes Matthew K. Fust's Form 4 filing for Neumora Therapeutics, Inc. (NMRA).
12 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 18 Oct 2024, 18:25.

Change

Previous filing in this sequence was filed on 20 Jun 2024.
Current net transaction value: -$243,923.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NMRA transaction

Common Stock

Options Exercise

Transaction value: $31,475
Shares: +3,783
Change %: +19%
Price: $8.32
Shares after: 23,883
Date: 17 Oct 2024
Ownership: Direct

NMRA transaction

Common Stock

Options Exercise

Transaction value: $15,822
Shares: +1,800
Change %: +7.5%
Price: $8.79
Shares after: 25,683
Date: 17 Oct 2024
Ownership: Direct

NMRA transaction

Common Stock

Options Exercise

Transaction value: $5,433
Shares: +2,156
Change %: +8.4%
Price: $2.52
Shares after: 27,839
Date: 17 Oct 2024
Ownership: Direct

NMRA transaction

Common Stock

Sale

Transaction value: $131,643
Shares: -7,739
Change %: -28%
Price: $17.01
Shares after: 20,100
Date: 17 Oct 2024
Ownership: Direct
Footnotes: F1, F2

NMRA transaction

Common Stock

Options Exercise

Transaction value: $54,542
Shares: +6,205
Change %: +31%
Price: $8.79
Shares after: 26,305
Date: 18 Oct 2024
Ownership: Direct

NMRA transaction

Common Stock

Options Exercise

Transaction value: $19,767
Shares: +7,844
Change %: +30%
Price: $2.52
Shares after: 34,149
Date: 18 Oct 2024
Ownership: Direct

NMRA transaction

Common Stock

Sale

Transaction value: $239,319
Shares: -14,049
Change %: -41%
Price: $17.03
Shares after: 20,100
Date: 18 Oct 2024
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NMRA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -3,783
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 17 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,783
Exercise price: $8.32
Footnotes: F4

NMRA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -1,800
Change %: -22%
Price: $0.000000
Shares after: 6,205
Date: 17 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,800
Exercise price: $8.79
Footnotes: F4

NMRA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -2,156
Change %: -2.3%
Price: $0.000000
Shares after: 93,430
Date: 17 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,156
Exercise price: $2.52
Footnotes: F4

NMRA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -6,205
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 18 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,205
Exercise price: $8.79
Footnotes: F4

NMRA transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -7,844
Change %: -8.4%
Price: $0.000000
Shares after: 85,586
Date: 18 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,844
Exercise price: $2.52
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 10, 2024.

Footnote F2

This transaction was executed in multiple trades in prices ranging from $17.00 to $17.045, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

This transaction was executed in multiple trades in prices ranging from $17.00 to $17.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F4

The shares subject to the option are fully vested and exercisable.